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Highlights 
 Bivalent ligands are research tools for GPCRs and their interacting complexes 
 Three opioid-nociceptin hybrid peptides were studied by biochemical 
pharmacology 
 Receptor binding and activation patterns of the peptides were sequence specific 
Abstract 
In an attempt to design opioid-nociceptin hybrid peptides, three novel bivalent ligands, 
H-YGGFGGGRYYRIK-NH2, H-YGGFRYYRIK-NH2 and Ac-RYYRIKGGGYGGFL-OH 
were synthesized and studied by biochemical, pharmacological, biophysical and molecular 
modelling tools. These chimeric molecules consist of YGGF sequence, a crucial motif in the 
N-terminus of natural opioid peptides, and Ac-RYYRIK-NH2, which was isolated from a 
combinatorial peptide library as an antagonist or partial agonist that inhibits the biological 
activity of the endogenously occurring heptadecapeptide nociceptin. Solution structures for the 
peptides were studied by analysing their circular dichroism spectra. Receptor binding affinities 
were measured by equilibrium competition experiments using four highly selective 
radioligands. G-protein activating properties of the multitarget peptides were estimated in 
[35S]GTPS binding tests. The three compounds were also measured in electrically stimulated 
mouse vas deferens (MVD) bioassay. H-YGGFGGGRYYRIK-NH2 (BA55), carrying N-
terminal opioid and C-terminal nociceptin-like sequences interconnected with GGG tripeptide 
spacer displayed a tendency of having either unordered or -sheet structures, was moderately 
potent in MVD and possessed a NOP/KOP receptor preference. A similar peptide without 
spacer H-YGGFRYYRIK-NH2 (BA62) exhibited the weakest effect in MVD, more -helical 
periodicity was present in its structure and it exhibited the most efficacious agonist actions in 
the G-protein stimulation assays. The third hybrid peptide Ac-RYYRIKGGGYGGFL-OH 
(BA61) unexpectedly displayed opioid receptor affinities, because the opioid message motif is 
hidden within the C-terminus. The designed chimeric peptide ligands presented in this study 
accommodate well into a group of multitarget opioid compounds that include opioid-non-opioid 
peptide dimer analogues, dual non-peptide dimers and mixed peptide- non-peptide bifunctional 
ligands. 
Keywords: radioligand binding, mouse vas deferens, opioid receptors, NOP receptor, 
nociception, bivalent ligands 
   
1. INTRODUCTION 
G protein-coupled receptors (GPCRs) are ancestrally related membrane proteins on 
various cells that mediate the physiological and pharmacological effect of most drugs, 
hormones and neurotransmitters. GPCRs are the largest family of proteins encoded in the 
human genome. One of the most important types of GPCRs is the opioid receptors [1–6]. Opioid 
family receptors consist of four closely related cell surface proteins expressed in all vertebrate 
animals examined to date. The three classical types of opioid receptors shown unequivocally to 
mediate analgesia in animal models and in humans are the mu- (MOP), delta- (DOP), and 
kappa- (KOP) opioid receptor proteins. The fourth and most recent member of the opioid 
receptor family described is the nociceptin or orphanin FQ receptor also called as NOP receptor 
or ORL-1 (opioid receptor like) receptor [7,8]. The role of NOP receptor and its ligands in 
mediating analgesia is not as clear, with both analgesic and hyperalgesic effects reported. 
Natural ligands for the opioid receptor subfamily are endogenous opioid peptides. They 
include Met- and Leu-enkephalin [9], β-endorphin [10], dynorphin A [11] and nociceptin or 
orphanin FQ [7,8]. Opioid peptides are easy and frequent targets for chemical modifications, 
so it is not surprising that a huge amount of synthetic opioid peptides have been reported with 
various structural modifications for reviews see [12–14] and [15–18]. Hybrid or bifunctional 
peptide or non-peptide ligands developed recently, bearing two pharmacophores, represent 
novel biochemical tools in investigating GPCRs and their interacting complexes. The pioneer 
synthetic bifunctional opioid peptide was a double enkephalin later named biphalin [19]. 
Biphalin (Tyr-D-Ala-Gly-Phe-NH-NH<-Phe<-Gly<-D-Ala<-Tyr) is an opioid octapeptide with 
a dimeric structure based on two identical pharmacophore portions, derived from enkephalins, 
joined "tail to tail" by a hydrazide bridge. Numerous structure-activity relationship studies 
(SAR) were performed in order to understand the elements responsible for the high activity of 
biphalin [20]. Beside biphalin, a number of other chimeric opioid peptides linked by spacer 
have been studied so far. Opioid peptides have often been combined with other bioactive 
neurotransmitters and peptide hormones that are involved in pain perception, e.g. substance P, 
neurotensin, cholecystokinin, cannabinoids, neuromedin ligands, etc. [21]. Such novel peptide 
chimeras (also called designed multiple ligands or twin or hybrid drugs), may interact 
independently with their respective receptor proteins.  
Here we describe and characterize three novel hybrid opioid peptides using in vitro 
displacement binding and functional [35S]GTPS binding assay as well as mouse vas deferens 
bioassay . These bivalent ligands (BA55 and BA62) are composed either of the minimum opioid 
   
tetrapeptide structure (Tyr-Gly-Gly-Phe; YGGF) or (Tyr-Gly-Gly-Phe-Leu; YGGFL) targeting 
the opioid receptors, and a NOP receptor recognizing synthetic sequence Ac-Arg-Tyr-Tyr-Arg-
Ile-Lys-NH2 (Ac-RYYRIK-NH2) isolated originally from combinatorial chemical libraries 
[22]. Ac-RYYRIK-NH2 and its related hexapeptides were reported to behave as partial agonists 
[22], therefore they are capable of antagonizing NOP receptor selective pure agonist ligands 
[23–27]. The related peptide fragments were either fused directly or connected via an arbitrary 
given short tripeptide spacer composed of three glycine residues (GGG). The structures of the 
three hybrid peptides are H-YGGFGGGRYYRIK-NH2, H-YGGFRYYRIK-NH2, Ac-
RYYRIKGGGYGGFL-OH. Combining the MOP/DOP/KOP receptor agonist structure with 
the NOP receptor partial agonist/antagonist sequence Ac-RYYRIK-NH2 would result in 
effective bivalent compounds targeting the individual opioid receptors and perhaps their 
interacting complexes, e.g., MOP/NOP or DOP/NOP receptor heterodimers. 
 
2. MATERIALS AND METHODS 
2.1. Chemicals 
All amino acid derivatives, resins (Rink-amide MBHA, 2-chlorotrityl resin) and 
coupling agents were purchased from IRIS Biotech GmbH (Marktredwitz, Germany), Reanal 
(Budapest, Hungary) or Fluka (Buchs, Switzerland). Solvents for synthesis and HPLC were 
from Molar Chemicals (Budapest, Hungary) or Merck Kft (Budapest, Hungary). Tris-HCl, 
MgCl2 x 6H2O, EGTA, NaCl, GDP, the GTP analogue GTPS, Bovine serum albumin (BSA), 
the [d-Ala2, d-Leu5] enkephalin (DADLE) and U-69,593 were purchased from Sigma-Aldrich 
(Budapest, Hungary). YGGF, Leu-enkephalin and nociceptin was obtained from Bachem 
Holding AG (Bubendorf, Switzerland). The Tyr-d-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO), the 
Ile5,6-deltorphin II (IleDelt II) were synthesized in the Laboratory of Chemical Biology group 
of the Biological Research Center (BRC, Szeged, Hungary) and the Ac-RYYRIK-NH2 was 
synthesized in the Research Group of Peptide Chemistry of MTA-ELTE, Budapest. The 
U50,488H was obtained from the Upjohn Company, (Kalamazoo, MI, USA) and the 
ethylketocyclazocine (EKC) was purchased from Sterling Winthrop (Rensselaer, NY, USA). 
The naltrindole, nor-BNI, and JTC-801 were purchased from Tocris Bioscience (Bristol, UK). 
The naloxone was kindly provided by the company Endo Laboratories DuPont de Nemours 
(Wilmington, DE, USA) and the cyprodime was a gift from Prof. Helmut Schmidhammer, 
Innsbruck University, Innsbuck, Austria. Ligands were dissolved in water and were stored in 1 
   
mM stock solution at −20 C. The radiolabelled GTP analogue, [35S]GTPS (specific activity: 
1000 Ci/mmol) was purchased from Hartmann Analytic (Braunschweig, Germany). 
[3H]DAMGO (specific activity: 38.8 Ci/mmol), [3H]IleDelt II (specific activity: 19.6 Ci/mmol) 
and [3H]HS665 (specific activity: 13.1 Ci/mmol) were radiolabelled by the Laboratory of 
Chemical Biology group in BRC (Szeged, Hungary) and were characterized previously. [3H]U-
69,593 (specific activity: 43.6 Ci/mmol) and [3H]Nociceptin (specific activity: 115.5 Ci/mmol) 
were purchased from PerkinElmer (Boston, USA). The UltimaGoldTM MV aqueous 
scintillation cocktail was purchased from PerkinElmer (Boston, USA). 
   
2.2. Circular dichroism (CD) spectroscopy 
Far-UV CD spectra were recorded at 25 C temperature on Jasco J-810 
spectropolarimeter on the peptide. The CD spectra were measured at between 260 and 185 nm 
with an optical pathlength of 1 mm, the peptide concentration was ~ 0.1 mg/ml in Milli-Q water. 
The bandwidth was 2 nm and data pitch 1.0 nm, the scan speed was set to 100 nm/min and the 
integration time was 1 sec. 10 spectra were accumulated and plotted. Far UV spectra were 
analized by CDSSTR method (dichroweb.cryst.bbk.ac.uk/html/home.shtml). 
Near-UV range: Typical spectral accumulation parameters were the scanning speed 50 
nm/min with 1 nm bandwidth and the 0.2 nm step resolution over wavelength range 240-325 
nm with five scans averaged for each spectrum. The temperature at the cuvette was controlled 
by Peltier-type heating system. The raw ellipticity data were converted into molar ellipticity 
([θ]/ deg*cm 2*dmol - 1) for the near-UV region. 
2.3. Molecular dynamics calculations 
The conformers were generated by simulated annealing and energy minimization 
method. An initial unrestrained molecular dynamics simulation was performed at 1000 K to 
override the conformational barriers. The trajectory was sampled every picoseconds and the 
resulting snapshots were annealed to 50 K for two picoseconds and then energy minimized by 
RMS gradient convergence criterion of 0.001. Molecular modelling was performed by the 
Tinker program package v. 6.3.3 (Software Tools for Molecular Design Washington University 
Medical School, USA). All molecular dynamics steps were performed using the amber99 force 
field and GBSA implicit solvent environment. Investigation of the secondary structure of the 
conformers was performed by the Stride program [28]. 
2.4. Animals  
In experiments designed for receptor binding assay: male and female Wistar rats (250–
300 g body weight) and male guinea pigs (~700 g body weight, LAL/HA/BR strain) were used. 
Rats were housed in the local animal house of BRC (Szeged, Hungary), while guinea pigs were 
housed in LAB-ÁLL Bt. (Budapest, Hungary). For MVD experiments NMRI mice (35-45 g) 
were used. Mice were purchased from Toxicoop (Budapest, Hungary) and they were housed in 
the local animal house of the Department of Pharmacology and Pharmacotherapy, Semmelweis 
University (Budapest, Hungary) in group of 5 animals /cage. 
   
Animals were kept in a temperature controlled room (21-24 oC) under a 12:12 light and dark 
cycle, allowed free access to tap water and standard rodent food until the time of sacrifice. The 
animals were handled humanely, in complete accordance with the European directive 
2010/63/EU on the protection of animals used for scientific purposes and the Hungarian Act 
for the Protection of Animals in Research (XXVIII.tv. 32.§). Both the number of rats and their 
suffering were minimized throughout our experiments.   
2.5. Peptide synthesis  
The peptides were synthesized by solid phase peptide synthesis method using Fmoc 
strategy on Rink-amide MBHA (H-YGGFGGGRYYRIK-NH2, H-YGGFRYYRIK-NH2) or on 
2-chlorotrityl resin (Ac-RYYRIKGGGYGGFL-OH). Amino acids were coupled as Fmoc 
derivatives by the DIC/HOBt coupling method in DMF. After removal of the last Fmoc group, 
the N-terminus was acetylated by acetic anhydride and DIEA. The crude products were purified 
by semipreparative RP-HPLC and the purified compounds were characterized by analytical RP-
HPLC and ESI-ion trap mass spectrometry.  
2.6. Rat and guinea pig brain membrane homogenate preparation for binding assays 
Animals were decapitated and rat or guinea pig brains were quickly removed. The brains 
were prepared according to a method previously described [29] and partly used for binding 
experiments and partly were further prepared for the [35S]GTPS binding experiments 
according to [30]. Briefly, the full brain (without cerebellum) were homogenized, centrifuged 
in ice-cold 50 mM Tris-HCl (pH 7.4) buffer and incubated at 37 oC for 30 min in a shaking 
water-bath for details see [31]. After incubation the centrifugation was repeated as described 
before and the final pellet was suspended in 50 mM Tris-HCl pH 7.4 buffer containing 0.32 M 
sucrose. For the [35S]GTPS binding experiments the final pellet of rat or guinea pig brain 
membrane homogenate was suspended in ice-cold TEM (50 mM Tris-HCl, 1 mM EGTA, 3 
mM MgCl2) buffer so that the desired protein concentration for the assay (~10 μg/ml) could be 
achieved. The proteins were stored at −80 oC until future use. 
2.7. Displacement binding assay 
In competition binding experiments the affinity of an unlabelled compound is analysed 
by measuring radioligand specific binding in the presence of increasing concentrations of the 
unlabelled compound in question. Aliquots of frozen rat brain membrane homogenates were 
   
suspended in 50 mM Tris-HCl buffer (pH 7.4). Membrane fractions containing 0.3–0.5 mg/ml 
of protein were incubated with crescent concentrations (10-10–10-5 M) of the unlabelled tested 
ligands and 1 nM of the radioligands. Incubation conditions for rat brain homogenates were as 
follows: for [3H]DAMGO and [3H] IleDelt II 35 °C for 45 min, for [3H]U-69,593 24 °C for 45 
min, for [3H]Nociceptin 30 °C for 30 min. In case of [3H]U-69,593 in guinea pig brain 
membrane homogenates (guinea pig brain has significantly more kappa receptors than rat 
brain). Additionally, unlabelled IleDelt II, U-69,593, DAMGO and nociceptin were also 
incubated together with their labelled counterparts in increasing concentrations (10-10–10-5 M) 
for control. For experiments performed with [3H]Nociceptin the incubation mixture also 
contained 50 mM Tris/HCl, 2.5 mM EGTA, 5 mM MgCl2 and 0.5 mg/ml fatty acid-free BSA 
(pH 7.4). The level of non-specific binding was determined in the presence of 10 mM unlabelled 
naloxone, U-69,593, nociceptin or naltrindole, while total binding was determined in the 
absence of cold compounds. The reaction was terminated by rapid filtration under vacuum 
(Brandel M24R Cell Harvester; Brandel Harvesters, Gaithersburg, MD), and washed three 
times with 5 ml ice-cold 50 mM Tris-HCl or 50 mM Tris/ HCl, 2.5 mM EGTA, 5 mM MgCl2, 
0.5% BSA (pH 7.4) in case of [3H]Nociceptin. The filtration was accomplished through 
Whatman GF/C ([3H]DAMGO, [3H]IleDelt II) or GF/B ([3H]U-69593 and [3H]Nociceptin) 
glass fibre filters (GE Healthcare, Little Chalfont, UK). The radioactivity was detected in 
UltimaGold MV aqueous scintillation cocktail (Perkin Elmer, Waltham, MA) with Packard 
Tricarb 2300TR LSC spectrometer. The competition binding assays were performed in 
duplicates and repeated at least three times. 
2.8. Functional [35S]GTPS binding experiments 
The functional [35S]GTPS binding experiments were performed as previously 
described by [32], with slight modifications. Briefly the rat brain membrane fractions (~10 μg 
protein per sample) were incubated at 30 C for 60 min in Tris-EGTA buffer (pH 7.4). The 
buffer was composed of 50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, 30 μM 
GDP, containing 20 MBq/0.05 cm3 [35S]GTPS (0.05 nM) and increasing concentrations (10-10 
– 10-5 M) of the tested compounds in the presence or absence of 10 µM receptor specific 
antagonist (cyprodime, naltrindole or norbinaltorphimine). The final volume was 1 ml. Total 
binding (T) was measured in the absence of the test compounds, while non-specific binding 
(NS) was determined in the presence of 10 μM unlabelled GTPS and subtracted from the total 
binding value, to determine the specific binding. Throughout this paper, G-protein activation is 
   
given as percentage over the specific [35S]GTPS binding obtained in the absence of receptor 
ligands (basal activity). The difference of total binding (T) and non-specific binding (NS) 
represents the basal activity and was defined as 100%. After incubation, bound and unbound 
[35S]GTPS were separated by vacuum filtration through Whatman GF/B glass fiber filters with 
a Brandel M24R Cell harvester. Filters were washed three times with 5 ml ice-cold buffer (pH 
7.4), and the radioactivity of the filters was measured in UltimaGOLD™ (Perkin Elmer) 
scintillation cocktail with a Packard TriCarb 2300TR counter. The experiments were performed 
in triplicates and repeated at least three times. 
2.9. Mouse Vas Deferens (MVD) bioassay 
Vasa deferentia from NMRI mice (35-45 g) were prepared as described previously [33]). 
Briefly, vasa deferentia (a single organ/bath) were mounted between two electrodes under an 
initial tension 0.1g in Mg2+ free Krebs solution aerated with carbogen (O2:CO2=95:5) at 31 C. 
Field electrical stimulation (upper ring, lower straight wire electrode arrangement) was used. 
The stimulation parameters were as follows: field stimulation, pairs (100 ms pulse distance) of 
rectangular impulses (1 ms pulse width, 9 V/cm i.e. supramaximal intensity) were repeated by 
10 s. The muscle contractions were monitored by computer, using a data recording and analysis 
system (LabChart 5, ADInstruments Pty LTD, Australia). 
2.10. Experimental Paradigms of MVD 
In the mouse vas deferens experiments, before adding the first dose of agonists, 30–40 
min equilibration was used for tissues under stimulation. For all experiments, only one 
concentration-effect curve for the agonists was constructed per tissue [34] and each of these 
was constructed in cumulative manner. The drug exposure was less than 2 min, and the 
administration cycle 12–18 min. Preparations were then washed out and allowed to regain their 
pre-drug twitch height. Then they were equilibrated for 20 min with antagonists (naloxone, 
JTC-801, naltrindole, nor-BNI), and without washing a single concentration of agonist was 
added. To determine dissociation constants of the antagonist, dose ratio (DR) values were 
obtained by the single-dose method described [35]. 
2.11. Data analysis 
Radioligand binding experiments were performed in duplicate and the [35S]GTPS 
binding assays were carried out in triplicate. Experimental data were analysed and graphically 
   
processed as means ± S.E.M in the function of the applied ligand concentration range in 
logarithm form. Points were fitted with the professional curve fitting program, GraphPad Prism 
6.0 (GraphPad Prism Software Inc., San Diego, CA, USA, www.graphpad.com), using non-
linear regression. In the radioligand competition binding assays the ‘One-site competition’, 
while in [35S]GTPS binding assays the ‘Sigmoid dose-response’ equation was applied to 
determine IC50 and Ki (unlabelled ligand affinity) and ligand potency (EC50) and the maximum 
G-protein efficacy (Emax), respectively. For IC50 and EC50 values standard error is only given in 
their logarithm form by the curve fitting program due to the data representation. The specific 
binding of either radiolabelled compound was calculated by the subtraction of non-specific 
binding from total binding and was given in percentage. The data was normalized to total 
specific binding, which was settled 100%, which in case of [35S]GTPS also represents the basal 
activity of the G-protein. In the MVD bioassay, the 50% effective concentration (EC50) and 
maximal effect (Emax) was determined from the non-linear regression (Hill 4 parameters 
equation) of individual logarithmic concentration-response curves. The equilibrium 
dissociation constant of antagonists (Ke) was calculated with the single-dose method [35]. 
Antagonist affinities (Ke values) were calculated as: Ke= [antagonist concentration]/dose ratio 
−1. Experimental data were analysed and graphically represented as means ± S.E.M with curve 
fitting program, SigmaPlot 11.0. (Systat Software, San Jose, CA). Differences between two 
data sets unpaired t-test with two-tailed P-value statistical analysis was used, while for three or 
more data sets one-way ANOVA with Tukey's post hoc test was performed to determine 
statistical significance. Significance was accepted at the P < 0.05 level. 
   
3. RESULTS 
3.1. Circular dichroism (CD) spectroscopy 
Three novel hybrid peptides composed of opioid (YGGF) and nociceptin-like 
(RYYRIK) building blocks were synthesized and studied. A detailed analysis of the different 
ECD (electron-capture dissociation) spectra of the bivalent peptides provided the following 
structural information: Table within the Fig. 1. shows the relative distributions of secondary 
structures observed. Spectral data collected at 25 °C were analysed by CDSSTR method using 
reference dataset: 3 [36]. Peptide BA55 has been associated with the unordered motive and the 
turns, while BA61 and BA62 the β-sheet and α-helix motives are dominant, respectively. Due 
to the aromatic amino acid content of these peptides the near-UV ECD region can also be 
informative (Fig. 1. B, C and D). All three peptides have similar spectral properties at all 3 
temperatures recorded: i) a negative band at around 280 nm (Lb of Tyr) disappearing at 85°C a 
bit more pronounced for BA61, ii) a positive band at about 260 nm (most probably Lb of Phe) 
and iii) the shoulder of a larger band (248 nm) positive at 5°C reversed in sign at 85°C. In 
summary, the atypical far-UV ECD spectra, with bands strongly influenced by electronic 
transitions arising from the aromatic residues suggest rather an unstructured polypeptide main 
chain, which otherwise could have some partial order unrevealed at lower T, completely 
vanishing at elevated temperature. 
3.2. Molecular dynamics calculations 
The effect of the structure of the peptides on the biological activity on the NOP receptor 
was related to their secondary structure in solution analysed by both experimental and 
theoretical methods. Due to the conformational flexibility of peptides, a widely used 
experimental method to investigate their secondary structure is the electronic circular dichroism 
(CD) spectroscopy. In silico investigation of flexible peptides can be performed by the 
conformational analysis of conformer ensembles. Here we analysed ensembles of 50000 energy 
minimized conformers generated by molecular dynamics (MD) simulation (Fig. 2.).  The 
binding activities shown for the NOP receptor can be correlated to the secondary structure 
patterns of the peptides. The amount of the turns present in the peptides seems to be proportional 
to the affinity, as in the most active BA61 turns were found in nearly 50%. Contrary to the 
turns, the presence of helices in the peptides showed a reverse effect, as the most helical BA62 
proved to be inactive on NOP receptor. The percentile ratios and the location of the different 
secondary structure elements distributed within the conformer ensembles were compared to the 
   
experimental results obtained by CD. The percentage of a specific secondary structure was 
calculated as follows: 
100 x (sum of the affected resides in the ensemble) / (sum of all residues in the ensemble) 
The negligible amount of beta strands in the conformers was in accordance of their absence in 
the CD spectra. The rank order of the overall amount of turns was the same as obtained by CD. 
In the case of helices, the helix content of the inactive BA62 was the highest, as expected. 
Besides the overall amount of the secondary structure elements their location was also 
investigated. The most abundant beta turn type IV distributed almost uniformly along the 
peptide chains. beta turn type I, the second highest amount turn type, mostly abounded close to 
the N-terminal in the most active BA61 but farther from the N-terminal in other two peptides 
(Figure turns). The distribution of helices in the peptides seems to be related to the RYYRIK 
segment (Figure helices). However, besides the core RYYRIK segment, the helical character 
seems to be prune to extend toward the nearby glycine rich regions too.  
3.3. Receptor binding assays and functional [35S]GTPS binding experiments 
Heterologous equilibrium competition curves are shown in Fig. 3. and these studies are 
summarized in Table 1. Each of the three peptides displaced the receptor type-selective 
radioligands with various affinities. The highest NOP receptor affinity was obtained with BA61 
(Ki 16 nM, Table 1.) confirming that the Ac-RYYRIK-NH2 N-terminal sequence carries NOP 
receptor interacting motifs. Most of the curves were accurately fitted by the ‘one binding site’ 
model. However, the curve for [3H]DAMGO / BA61 the ’two site fit’ was really perfect with 
Ki values of 0.02 nM (high affinity site) and 2.4 μM (low affinity site), respectively. The Ki 
values of BA61 were 0.9 and 155 nM measured with [3H]U-69,593 suggesting again biphasic 
interaction in the case of KOP receptor (‘two site fit’ calculation). Moreover, the displacement 
curve of this competition was not complete (Fig. 3. C panel) with substantial residual binding 
activity (around 50%). The apparent high affinities of H-YGGF-OH and BA61 in the KOP 
receptor assay (Fig. 3. C panel) were also accompanied by higher residual binding levels. 
Binding selectivity ratios were calculated as quotients of the corresponding Ki values 
(Table 2.), while % relative affinity values (Table 2. last column) were calculated according 
to [37]. BA55 is characterized by higher KOP/NOP receptor preference, although sequence 
predictions suggested rather a MOP/DOP receptor selectivity for BA55. BA61 peptide exhibits 
NOP receptor preference (75%), while the characteristic target for the peptide BA62 is the DOP 
receptor (66%). 
   
Agonist induced and receptor mediated G-protein activation was studied by [35S]GTPS 
binding assays performed on rat or guinea pig brain membranes (Fig. 4.). All three bivalent 
peptide ligands effectively stimulated the activity of regulatory G-proteins in rat brain 
membranes with maximal stimulation levels of 149:126:149 % for BA55:BA61:BA62, 
respectively (Table 3.). On the basis of these Emax values and those of Leu-enkephalin (H-
YGGFL-OH), BA55 and BA62 are full agonists, while peptide BA61 seems to be a partial 
agonist ligand. In guinea pig brain membrane fractions, containing mainly KOP receptors, the 
stimulation order was BA55  BA62 > BA61, indicating again the partial agonist nature of 
BA61. The effects of the three hybrid peptides were also compared with those of the simple 
mixtures of their peptide building components. Thus, curves for the mixtures were substantially 
different from the curves depicting the real hybrid compounds (see Table 3. for significant 
differences).  
Antagonism by receptor type-selective ligands was also studied in [35S]GTPS binding 
experiments (Fig 5.). Stimulating effect of BA55 was significantly antagonised by DOP 
receptor, KOP receptor and NOP receptor antagonists, but not by cyprodime, a MOP receptor 
selective antagonist. G-protein activation by BA61 was substantially inhibited (significance 
level was ** or ***) in the presence of MOP receptor , DOP receptor  and NOP receptor 
antagonists, while not with nor-BNI, the most selective KOP receptor  antagonist, indicating 
that interaction of BA61 with the KOP receptor is weaker. Activating effect of the third hybrid 
peptide, BA62 was effectively antagonised by NOP receptor, DOP receptor and KOP receptor 
antagonist, but similarly to BA55, it was not inhibited by cyprodime. This suggests again that 
the MOP receptor is weakly involved in mediating the effects of these two peptides.  
 
3.4  Mouse vas deferens bioassay 
 
Fig. 6. depicts that the BA61, BA55, BA62 similarly to reference compounds inhibited 
the electrically-evoked MVD muscle contractions in concentration dependent manner. In MVD 
bioassay the EC50 (nM) values were 160, 3860, 19400 for BA61, BA55, BA62, respectively 
(Table 4.). BA61 was lesser potent than any of the reference compounds but about 24- and 121-
fold more potent than BA55 or BA62. The average Emax was 100 % for each compounds tested 
in the present work (Table 4.). The DOP receptor antagonist naltrindole (NTI) Ke values against 
BA61, BA55, BA62 and [D-Ala2,D-Leu5] enkephalin (DADLE, DOPr agonist) were all within 
the range of 0.14−1.06 nM. The Ke (nM) value of norbinaltorphimine (nor-BNI, KOPr 
   
antagonist) against BA55, BA62 and EKC (KOPr agonist) were 1.25 ± 0.41 (n=3), 0.41 ± 0.12 
(n=4) and 0.51 ± 0.17 (n=3), respectively (Table 4.). On the other side the naloxone (NX) Ke 
values against BA55 and BA62 were 14.05 ± 2.7 (n=5) and 3.8 ± 0.8 (n=5) nM, respectively. 
The calculated Ke value of NX against DAMGO (typical MOPr agonist) was 1.01 ± 0.14 (n=3) 
and of JTC-801 against nociceptin (NOPr agonist) was 480 ± 72 (n=3) nM. 
  
4 DISCUSSION 
Different types of pain of moderate to severe intensity is often treated with opioid 
compounds with variable success. However, central and peripheral origin unwanted effects 
such as respiratory depression, constipation, tolerance and dependence are among main factors 
that limit the use of opiate therapy. One strategy to overcome the major side effects and to 
prolong the analgesic efficiency of the applied drugs involves the creation of bi- or 
multifunctional compounds which contain hybridized structures [21,38]. Combination of opioid 
agonist and antagonist pharmacophores in a single molecule has been considered and 
extensively investigated e.g. [39], but opioids have also been combined with other bioactive 
neurotransmitters and peptide hormones that are involved in pain perception (e.g. neurotensin, 
neurokinins, such as substance P, cholecystokinin, cannabinoids, etc. [40–42].  
Three chimeric peptides were synthesized and studied in the current work. Amino acid 
sequence of the opioid peptide building blocks (YGGF) was selected according to the message-
address model [43]), while the composition of the other pharmacophore (RYYRIK) based on 
artificial hexapeptide sequences isolated from a combinatorial peptide library [22]. Ac-
RYYRIK-NH2 and Ac-RYYRIK-ol have been reported to display NOP receptor partial agonists 
with full antagonist properties in the presence of the pure agonist N/FQ [24–26,44]. 
Combination of NOP receptor antagonists with MOP receptor agonists would be perspective as 
analgesics, although for that reason non-peptide structures could be optimal. Transmembrane 
helix II of the NOP receptor was shown to be involved in the recognition of the Ac-RYYRIK-
NH2 hexapeptide by photoaffinity labelling [45] while another molecular modelling and 
docking study described that both nociceptin and Ac-RYYRIK-NH2 can able to activate NOP 
receptor and their receptor-bound conformations have similar 3D structures [46]. 
   
Our novel peptide hybrids represent designed structures targeting at least two different 
GPCRs and perhaps their interacting complexes. Two peptides contain the YGGF opioid 
message motif at their N-terminus, and this region is followed by the C-terminally located Ac-
RYYRIK-NH2 hexapeptide sequence. The two pharmacophores were connected directly in 
BA62, or interconnected with a triglycine (GGG) spacer sequence in BA55. The third chimeric 
peptide ligand bears a Ac-RYYRIK-NH2 sequence at the N-terminus, that was combined with 
the YGGF opioid receptor recognising motif or message sequence [43] via a triglycine (GGG) 
spacer. It is worth noting that, our peptide sequences are different from those reported by [47]. 
These authors described MOP/NOP receptor hybrid peptides consisting of full or partial 
dermorphin sequences found originally in frog skin [48]), fused with the Dooley’s Ac-
RYYRIK-NH2 hexapeptide [47]. 
Based on the different abundance in the peptides, the presence of turns close to the N-
terminal may be important for the activity at NOP receptor. The presence of helices close to the 
N-terminal is contradictory. Due to its low percentage in BA61, the effect of helix on the affinity 
is presumably negligible and the RYYRIK segment is capable of exerting its effect. Comparing 
BA55 and BA62, despite they uniform N-terminal segment, the latter is inactive. This may be 
the consequence of helical segments close to N-termini, starting at Gly3. In addition, BA62 is 
the most abundant in helical segments according to CD spectra. In BA55, the helical segments 
are shifted from 3 residue away from the N-terminal, by the amount of the Gly-Gly-Gly spacer 
between the nociceptin fragment YGGF and RYYRIK. It seems that the helicity induced by 
Ac-RYYRIK-NH2 less disturbed the structure of the N-terminal fragment in BA55 than did in 
BA62. Additionally, BA55 is less helical than BA62, according to CD. 
In terms of binding affinity, the rank order of potency of the three peptides was BA61 > 
BA55 > BA62 at the KOP receptor. The good KOP receptor activity of BA55 and BA62 is not 
surprising, because the accumulation of positively charged amino acid side chains (two 
arginines and one lysine, R..R.K) at the opioid address domain is present in various 
prodynorphin- (PDYN) derived endogenous opioid peptides [49], including dynorphin A 1-17 
(RR...K.K), dynorphin B or rimorphin (RR..K...) and -neo-endorphin (RK..K). These data are 
consistent with our hypothesis that appropriate modifications in the address domain of 
dynorphin analogues may affect efficacy. Our results confirm also the importance of the opioid 
"message" displayed by many opioid ligands but also suggest a potential role of receptor 
recognition and activation that may be mediated by EL2 through interactions with the "address" 
component of dynorphin-like peptides [50]. The good MOP and KOP receptor affinities of 
BA61 (Ac-RYYRIKGGGYGGF-OH) were not expected, because this peptide has no N-
   
terminal tyrosine (Tyr, Y) at all, which is common in all endogenous opioid peptides, -
endorphin, enkephalins, dynorphins and neo-endorphins. Moreover, the original opioid 
message tetrapeptide is hidden at the C-terminus of BA61, so the C-terminal address region of 
this synthetic oligopeptide ligand has no positively charged amino acids important for the KOP-
receptor recognition. The high KOP receptor affinity was not observed among the Dooley’s 
hexapeptide analogues described earlier [24–27,51]. 
Peptides having the opioid message sequence YGGF at the N-terminus remained 
comparable full agonists with Leu-enkephalin (YGGFL) when their G-protein activating 
properties were studied in [35S]GTPS binding experiments (Fig. 3.). The Emax (efficacy) values 
went up to 149, 149 and 184% for BA55, BA62 and Leu-enkephalin, respectively. The third 
peptide starting with Ac-RYYRIK-NH2 sequence possesses partial agonist properties reaching 
an Emax value of 126% (Table 3.). Ac-RYYRIK-NH2 hexapeptides were consistently found to 
be partial agonists and/or antagonist ligands in a variety of biochemical and pharmacological 
assays [24–27,52]. It is also worthy to mention here that in the G-protein stimulation assays, 
simple mixtures composed from the parent peptide components of the hybridised ligands 
behaved differently when their effects were compared to the multitarget fused sequences 
bearing real chemical connections, i.e., covalent bonding. Ac-RYYRIK-NH2 was able to inhibit 
the stimulation by Leu-enkephalin (Fig. 3. B panel), when it was present in the mixture, 
indicating that the Dooley’s peptide has opioid antagonist activity in addition to the well-known 
antagonism observed at the NOP receptors. In guinea pig brain membranes, where KOP 
receptors are predominant, BA55 (Fig. 3. D panel) and BA62 (Fig. 3. F panel) mediated effects 
were additive by mixing them with the opioid tetrapeptide YGGF, the latter represents a 
minimum structure for opioid receptor activation [53]. 
BA55 and BA62 were significantly antagonized by the KOP receptor specific nor-
binaltorphimine (nor-BNI) in the [35S]GTPS binding experiments (Fig. 4. D and F panels), 
while BA61 was not affected by the addition of nor-BNI (Fig. 4. E panel). This phenomenon 
supports the KOP receptor preference of those hybrid peptides that contain the N-terminal 
opioid message sequence YGGF in the correct, N-terminally position. Interestingly enough, 
when the opioid tetrapeptide is located at the C terminus of the hybrid compound BA61, only 
nor-BNI was not able to antagonize the stimulation, while JTC-801, cyprodime and naltrindole 
produced significant inhibitions. 
For a comparison, we extended our study to examine the pharmacological properties of 
the test peptides in MVD, which hosting MOP, DOP, KOP and NOP receptors. The order of 
   
potency in this tissue was BA61 BA55 BA62. Applying different opioid receptor subtype 
antagonists revealed that, BA55 and BA62 showed non selective opioid receptor subtype 
mediated action (MOP, DOP and KOP receptor), whereas BA61 displayed affinity for DOP 
and NOP but not for KOP receptor. Based on the above mentioned data, the test peptides 
displayed potency order that matches what was determined in the binding assay. This similarity 
was also found in the action of BA55 and BA62 for KOP. In addition, the two peptides showed 
DOP receptor-mediated effect. However, the selectivity of these two peptides for DOP receptor 
was less that of DADLE, indicated by dissociation constants (Table 4). The involvement of 
DOP and KOP receptor in the action of BA55 and BA62 is not surprising, since the two peptides 
have the same address and message domains. In contrast, BA61 has different N-terminal 
domain (Ac-R), and yet different C-terminal (carboxyl group). This observation is in good 
agreement with previous results, according to which the free carboxyl group containing 
enkephalins preferred DOP receptors [54,55]. Moreover, keeping in mind that BA61 has N-
terminal preferred by NOP receptor [24–26,44]. Consequently, the observed pharmacological 
effect of this peptide might be stand on these changes. Indeed, we could not parallel measure 
the contribution of NOP and DOP receptor  mediated by BA61, because MVD hosting all opioid 
receptor subtypes but the DOPr reserve is high [56,57]. This tendency makes MVD very 
sensitive for DOP receptor mediated effect of BA61. Therefore, we measured the effect of JTC-
801 against BA61 in the presence of NTI, a selective DOP receptor antagonist. Applying this 
strategy we could show the action of BA61 on NOP receptor. 
Based on the different abundance in the peptides, the presence of turns close to the N-
terminal may be important for the activity at NOP receptor. The presence of helices close to the 
N-terminal is contradictory. Due to its low percentage in BA61, the effect of helix on the affinity 
is presumably negligible and the Ac-RYYRIK segment is capable of exerting its effect. 
Comparing BA55 and BA62, despite their uniform N-terminal segment, the latter is inactive. 
This may be the consequence of helical segments close to N-termini, starting at Gly3. In 
addition, BA62 is the most abundant in helical segments according to CD spectra. In BA55, the 
helical segments are shifted from 3 residue away from the N-terminal, by the amount of the 
Gly-Gly-Gly spacer between the nociceptin fragment YGGF and RYYRIK. It seems that the 
helicity induced by RYYRIK disturbed less the structure of the N-terminal fragment in BA55 
than did in BA62. Additionally, the location of the helices in BA55 is very similar to that in 
helix-constrained nociceptin analogues [58] (Fig. 2) allowing a nociceptin-like activation 
mechanism. A typical conformer of peptide BA55 having helical C-terminal tail is shown in 
Fig 2C.  
   
Summarizing the results we can tell that each of the three novel hybrid peptides carries 
either opioid- or NOP receptor interacting properties or both, as expected during the design. 
One of the original goal that was the combination of the natural opioid agonist tetrapeptide 
“message” region with the artificial NOP-receptor selective antagonist (RYYRIK) peptide 
sequence is fulfilled, although some of the data did not yield the desired specific result.  On the 
other hand, fine selectivity for an individual receptor of the novel peptides was not expected, 
because these are targeting at least two receptor proteins.  The resulting hybrid structures can 
at least partly served as bivalent compounds for receptor labelling.  Our most important and 
surprising observation is that BA61 behaved as partial agonist at the opioid receptors 
notwithstanding there is no N-terminal opioid “message” sequence in its structure.  Taken 
together, the tridecapeptide H-YGGFGGGRYYRIK-NH2 (BA55) is moderately potent in the 
MVD bioassay, it exhibits a KOP/NOP receptor preference, and it has mainly unordered 
conformations in solution. The shorter hybrid decapeptide composed of opioid message and 
NOP receptor / nociceptin address domains, H-YGGFRYYRIK-NH2 (BA62), exhibited the 
weakest inhibition on the mouse vas deferens, it has more -helix in its structure, and this 
chimeric peptide has been the most efficacious agonist in the G-protein stimulation assays. The 
third bivalent compound, the tetradecapeptide Ac-RYYRIKGGGYGGFL-OH (BA61) seems 
to be a quaint KOP receptor ligand, although its amino acid sequence is completely differing 
from those of the kappa-receptor selective endogenous opioid peptides. Bearing a NOP receptor 
recognising hexapeptide sequence, the high affinity of BA61 toward the NOP receptor has also 
been restored. Experiments on receptor co-expressing cell lines are in progress to examine the 
effects of these hybrid peptides on MOP-NOP receptor heterodimers. 
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Figures and legends 
 
 
 
 
Fig 1. Far (left) and near UV ECD spectra of the three hybrid peptides. A: Far UV spectra 
measured at 25°C. Temperature dependent near-UV spectra at B: 5°C, C: 35°C and  D) 85°C 
of BA55 (black), BA61 (red) and BA62 (blue). 
 
   
 
 
 
Fig. 2. Distribution of abundant secondary structures along the peptide sequences. Alpha-
helices, more abundant highlighted in magenta (A); Starting positions of beta turns type I (B). 
Amino acid numbering is shown at the bottom. (C) Conformer of BA55 possessing α-helix in 
the Arg8-Ile12 region. Backbone of the helical part is marked by magenta ribbon. Carbon, 
hydrogen, nitrogen and oxygen atoms are colored in cyan, white, blue and red, respectively. 
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Fig. 3. Displacement of [3H]DAMGO, [3H]Ile5,6Deltorphin II, [3H]U69,593 and 
[3H]Nociceptin radioprobes by the hybrid peptides and reference ligands. A) MOP receptor, B) 
DOP receptor, C) KOP receptor, D) NOP receptor assays were done in duplicates and repeated 
at least three times. The equilibrium competition binding experiments were performed in rat 
(A, B and D) and in guinea pig (C) brain membrane homogenates.  
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Fig. 4. Peptide agonist induced activation of G-proteins in rat brain (A-C) and in guinea pig 
brain (D-F) membranes. Points represent means  S.E.M. for at least three experiments 
performed in triplicate. ‘Mixture’ means that the opioid receptor targeting YGGF or YGGFL 
and the NOP receptor targeting Ac-RYYRIK-NH2 peptide fragments were concurrently present 
in the reaction tubes without their chemical cross-linking. 
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Fig. 5. Effects of opioid family receptor-type specific antagonist ligands on the G-protein 
activation by the hybrid peptides. Maximal stimulation (Emax) values were determined by 
analyzing full dose-response curves. Columns shown represents mean values ± S.E.M. All 
antagonists were used in 10 µM concentration. (A-C) Rat brain studies with selective 
antagonists for two classical opioid receptor (MOPr: cyprodime / Cyp; DOPr: naltrindole / NTI) 
and for the NOPr: JTC-801. **p < 0.01 and ***p < 0.001, and ****p < 0.0001 vs. control group 
(one way ANOVA followed by Bonferroni Multiple Comparison post hoc test). (D-F) 
Experiments on KOPr of guinea pig brain membranes using nor-binaltorphimine / nBNI as 
selective antagonist. ****p < 0.0001 vs. control group (unpaired t-test with Welch’s correction, 
two-tailed P value). 
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Fig. 6. Concentration-response curves for the bivalent peptides and reference opioid 
compounds on the electrically evoked contractions of the mouse vas deferens. Data are 
presented as mean ± S.E.M. 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Table 1. Evaluation of the three bivalent peptides and reference compounds in radioligand binding assays 
 
Affinity, pIC50 ± S.E.M.   (Ki, nM) 
Compounds [3H]DAMGO 
(MOPr)a 
[3H]Ile5,6Deltorphin II 
(DOPr )a 
[3H]U-69,593 
(KOPr)b 
[3H]Nociceptin 
(NOPr)a 
Selective ligands:     
   DAMGO  (MOPr) 7.92 ± 0.08 (4.15) n.d. n.d n.d 
   Ile5,6Deltorphin II  (DOPr) n.d. 8.16 ± 0.12 (1.3) n.d n.d. 
   U-69,593  (KOPr) n.d. n.d. 7.7 ± 0.07 (11) n.d. 
   Nociceptin  (NOPr) n.d. n.d. n.d. 8.5 ± 0.06 (2.8) 
   Ac-RYYRIK-NH2 n.d. n.d. n.d 8.4 ± 2.52 (4.2) 
Fused hybrid peptides:      
   H-YGGFGGGRYYRIK-NH2 BA55 5.72 ± 0.16 (743) 5.96 ± 0.2 (387) 6.9 ± 0.1 (58) 6.56 ± 2.38 (91) 
   Ac-RYYRIKGGGYGGFL-OH BA61§ 10.6 ± 0.8 (0.02)§ 7.55 ± 0.27 (73) 8.8 ± 0.2 (0.9)§ 7.75 ± 3.32 (16) 
   5.25 ± 0.2 (2451)§  6.56 ± 0.3 (155)§  
   H-YGGFRYYRIK-NH2 BA62 5.24 ± 0.45 (2530) 6.3 ± 0.35 (28) 6.8 ± 0.1 (71) 6.68 ± 0.26 (244). 
 
§ Results of two site fit exhibiting high-affinity binding site Ki value (upper row) and low-affinity binding site Ki (lower row) value, 
respectively. 
 
 
   
 
Table 2. Receptor-type selectivity comparisons for the hybrid peptides 
Peptides Binding selectivity ratios§ % relative affinity# 
 MOPr / DOPr MOPr / KOPr MOPr / NOPr DOPr / KOPr DOPr / NOPr KOPr / NOPr MOP:DOP:KOP:NOP 
BA55 1.9 13 8.2 6.7 4.3 0.6 4:8:54:34 
BA61 34 16 153 0.5 4.6 9.7 0.5:16:8:75 
BA62 90 36 10 0.4 0.1 0.3 1:66:26:8 
§ Binding selectivity ratios were calculated from Ki values.  Ki-s for BA61/[
3H]DAMGO and BA61/[3H]U-69,593 were calculated using values of 
the lower affinity sites. 
# Per cent relative affinities were quantified according to the formula given by Kosterlitz and Paterson (1980):   
 
 
   
 
Table 3. Summarized data of G-protein activation by the three chimeric peptides and their parent peptide sequences 
 
Peptides Rat brain membranes Guinea pig brain membranes 
Potency 
 pEC50 ± S.E.M. (EC50, nM) 
Efficacy 
% Emax, ± S.E.M. 
Potency 
pEC50 ± S.E.M. (EC50, nM) 
Efficacy 
% Emax, ± S.E.M 
Ac-RYYRIK-NH2 8.76 ± 0.21 (2) 121 ± 1 5.57 ± 0.35 (2723 120 ± 5 
H-YGGF-OH 5.63 ± 0.59 (2342) 119 ± 6 7.07 ± 0.48 (85) 108 ± 3 
Mixture 1 § 6.61 ± 0.37 (247) 112 ± 2 7.86 ± 2.03 (14) 121 ± 1 
Leu-enkephalin 7.21 ± 0.11 (62) 184 ± 4 7.18 ± 0.27 (67) 126 ± 3 
Mixture 2 & 6.42 ± 0.14 (381) 164 ± 3@ 6.37 ± 0.18 (424) 128 ± 2 
BA55  6.26 ± 0.18 (388) 149 ± 5 5.98 ± 0.11 (1039) 120 ± 1 
BA61 6.42 ± 0.15 (430) 126 ± 2 5.72 ± 0.60 (1929) 110 ± 4 
BA62 5.97 ± 0.15 (442) 149 ± 4 5.81 ± 0.32 (1560) 120 ± 3 
   § Mixture 1:  Ac-RYYRIK-NH2 + H-YGGF-OH, without chemical cross-linking of the components 
   & Mixture 2:  Ac-RYYRIK-NH2 + H-YGGFL-OH, without chemical cross-linking of the components 
   @ Significantly different from Ac-RYYRIK-NH2 (***p<0.001) ANOVA followed by Bonferroni’s post hoc test. 
 
 
 
 
 
 
 
 
 
 
   
Table 4. Characterization of the three bivalent peptide ligands and reference opioid agonist compounds in mouse vas deferens (MVD) bioassay. 
Ligands 
EC50 (nM)  ± S.E.M.  Ke values for antagonists ± S.E.M. (nM) 
  Naloxone (NX) Naltrindole (NTI) nor-BNI JTC-801 
DAMGO 30 ± 4 1.01 ± 0.14 * 9.05 ± 1.46 * 
DADLE 0.58 ± 0.06 * 0.13 ± 0.02 * * 
EKC 5.2 ± 1.3 7.9 ± 0.54 1.11 ± 0.18 0.51 ± 0.17 * 
Nociceptin 62 ± 4 * * * 480 ± 72 
BA55 3860 ± 79 14.05 ± 2.7 1.06 ± 0.23 1.25 ± 0.41 * 
BA61 160 ± 6 17.4 ± 4.45 0.16 ± 0.02 1.26 ± 0.4 3330 ± 765 
BA62 19400 ± 142 3.8 ± 0.8 1 ± 0.3 0.41 ± 0.12 n.d. 
The experiments were repeated at least three times. n.d.:  not determined; *:  no antagonist action, NX: naloxone, general opioid antagonist; 
NTI: naltrindole, DOP receptor antagonist; nor-BNI, norbinaltorphimine, KOP receptor antagonist; JTC-801: NOP receptor antagonist 
 
 
